BRPI0614080A2 - Composição e método para a preparação de uma cefalosporina nanoparticulada, para o tratamento de doença bacteriana e para a prevenção e/ou tratamento de osteoporose - Google Patents
Composição e método para a preparação de uma cefalosporina nanoparticulada, para o tratamento de doença bacteriana e para a prevenção e/ou tratamento de osteoporoseInfo
- Publication number
- BRPI0614080A2 BRPI0614080A2 BRPI0614080A BRPI0614080A BRPI0614080A2 BR PI0614080 A2 BRPI0614080 A2 BR PI0614080A2 BR PI0614080 A BRPI0614080 A BR PI0614080A BR PI0614080 A BRPI0614080 A BR PI0614080A BR PI0614080 A2 BRPI0614080 A2 BR PI0614080A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- nanoparticulate
- cephalosporin
- composition
- osteoporosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
COMPOSIÇÃO E MÉTODOS PARA A PREPARAÇÃO DE UMA CEFALOSPORINA NANOPARTICULADA, PARA O TRATAMENTO DE DOENÇA BACTERIANA E PARA A PREVENÇÃO E/OU TRATAMENTO DE OSTEOPOROSE. A presente invenção é dirigida a composições que incluem um antibiótico nanoparticulado tendo biodisponibilidade aperfeiçoada. Preferivelmente, o antibiótico compreende partículas de cefalosporina nanoparticuladas com um tamanho de partícula médio eficaz de menos que cerca de 2000 nm e é útil no tratamento de infecção bacteriana. A invenção também se relaciona a uma composição de liberação controlada compreendendo uma cefalosporina ou uma cefalosporina nanoparticulada que, em operação, fornece a droga de uma maneira pulsada ou bimodal para o tratamento de infecção bacteriana. As partículas de cefalosporina nanoparticuladas podem ser formuladas como um sistema de administração de droga de liberação controlada por meio do qual as partículas são revestidas uma ou mais vezes com um ou mais materiais de revestimento de polímero hidrofílico ou hidrofóbico natural ou sintético ou dispersas através de toda uma matriz de polímero hidrofílico e/ou hidrofóbico natural ou sintético.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68126505P | 2005-05-16 | 2005-05-16 | |
PCT/US2006/018835 WO2008010784A1 (en) | 2005-05-16 | 2006-05-16 | Nanoparticulate and controlled release compositions comprising a cephalosporin |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0614080A2 true BRPI0614080A2 (pt) | 2017-07-25 |
Family
ID=38957038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0614080A BRPI0614080A2 (pt) | 2005-05-16 | 2006-05-16 | Composição e método para a preparação de uma cefalosporina nanoparticulada, para o tratamento de doença bacteriana e para a prevenção e/ou tratamento de osteoporose |
Country Status (14)
Country | Link |
---|---|
US (1) | US20090269400A1 (pt) |
EP (1) | EP1915139A1 (pt) |
JP (1) | JP2008540691A (pt) |
KR (1) | KR20080026109A (pt) |
CN (1) | CN101287453A (pt) |
AU (1) | AU2006344711A1 (pt) |
BR (1) | BRPI0614080A2 (pt) |
CA (1) | CA2609296A1 (pt) |
EA (1) | EA200702518A1 (pt) |
IL (1) | IL187431A0 (pt) |
MX (1) | MX2007014363A (pt) |
NO (1) | NO20076456L (pt) |
WO (1) | WO2008010784A1 (pt) |
ZA (1) | ZA200709761B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2498903A4 (en) * | 2009-11-09 | 2013-10-30 | Univ Texas | METHOD USING EMULSION MATRIX FOR FORMING SMALL PARTICLES OF HYDROPHOBIC AGENTS WITH SURFACE ENRICHED HYDROPHILIC CHARACTER BY ULTRA FAST FREEZING |
CN101874784B (zh) * | 2010-03-18 | 2011-12-14 | 贝沃特医药技术(上海)有限公司 | 析出结晶药物缓控释微球粒及其制备方法 |
WO2011146583A2 (en) | 2010-05-19 | 2011-11-24 | Elan Pharma International Limited | Nanoparticulate cinacalcet formulations |
WO2014033077A1 (en) | 2012-08-28 | 2014-03-06 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at| least one of them is in the form of mini-tablets |
CN103980480B (zh) * | 2013-02-07 | 2018-08-17 | 杨子剑 | 一种接枝药物的聚合物的制备和用途 |
KR101509168B1 (ko) * | 2013-06-10 | 2015-04-06 | 한국화학연구원 | 세팔로스포린 항생제의 서방형 제제 및 이를 포함하는 서방형 약제학적 조성물 |
CN103330697B (zh) * | 2013-06-27 | 2015-03-11 | 深圳致君制药有限公司 | 一种头孢丙烯胶囊及其制备方法 |
RO132297A2 (ro) * | 2014-12-01 | 2017-12-29 | Sun Pharmaceutical Industries Limited | Compoziţie cu cefpodoxim proxetil cu eliberare extinsă |
CN112675152A (zh) * | 2020-12-25 | 2021-04-20 | 厦门金达威生物科技有限公司 | 一种nmn缓释肠溶性微胶囊及其制备方法 |
CN115487154B (zh) * | 2022-11-17 | 2023-02-21 | 山东国邦药业有限公司 | 一种盐酸多西环素颗粒剂的制备方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU642066B2 (en) * | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
AU660852B2 (en) * | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
US5298262A (en) * | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
US5340564A (en) * | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
US5336507A (en) * | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
US5326552A (en) * | 1992-12-17 | 1994-07-05 | Sterling Winthrop Inc. | Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants |
US5264610A (en) * | 1993-03-29 | 1993-11-23 | Sterling Winthrop Inc. | Iodinated aromatic propanedioates |
US5935496A (en) * | 1993-04-29 | 1999-08-10 | Morton International, Inc. | Salt pelletizing method |
TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
US5718388A (en) * | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
US5872104A (en) * | 1994-12-27 | 1999-02-16 | Oridigm Corporation | Combinations and methods for reducing antimicrobial resistance |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
AT413383B (de) * | 1998-01-09 | 2006-02-15 | Sandoz Ag | Verfahren zur isolierung eines diastereoisomerengemisches von cefpodoxim proxetil |
JP4613275B2 (ja) * | 1998-11-02 | 2011-01-12 | エラン ファーマ インターナショナル,リミティド | 多粒子改質放出組成物 |
IN191496B (pt) * | 1999-07-30 | 2003-12-06 | Ranbaxy Lab Ltd | |
KR100342944B1 (ko) * | 1999-11-08 | 2002-07-02 | 민경윤 | 고순도 세프포독심 프록세틸의 제조방법 |
AU2001255515A1 (en) * | 2000-09-20 | 2002-04-02 | Skyepharma Canada Inc. | Stabilised fibrate microparticles |
MXPA03007678A (es) * | 2001-02-27 | 2004-03-16 | Ranbaxy Lab Ltd | Composicion farmaceutica oral de proxetil cefpodoxima. |
US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
ATE419835T1 (de) * | 2002-05-06 | 2009-01-15 | Elan Pharma Int Ltd | Nystatin-nanopartikelzusammensetzungen |
IL160095A0 (en) * | 2004-01-28 | 2004-06-20 | Yissum Res Dev Co | Formulations for poorly soluble drugs |
-
2006
- 2006-05-16 AU AU2006344711A patent/AU2006344711A1/en not_active Abandoned
- 2006-05-16 MX MX2007014363A patent/MX2007014363A/es not_active Application Discontinuation
- 2006-05-16 EA EA200702518A patent/EA200702518A1/ru unknown
- 2006-05-16 BR BRPI0614080A patent/BRPI0614080A2/pt not_active IP Right Cessation
- 2006-05-16 CN CNA2006800251446A patent/CN101287453A/zh active Pending
- 2006-05-16 US US11/568,825 patent/US20090269400A1/en not_active Abandoned
- 2006-05-16 JP JP2008525989A patent/JP2008540691A/ja active Pending
- 2006-05-16 EP EP06849781A patent/EP1915139A1/en not_active Withdrawn
- 2006-05-16 CA CA002609296A patent/CA2609296A1/en not_active Abandoned
- 2006-05-16 KR KR1020077029466A patent/KR20080026109A/ko not_active Application Discontinuation
- 2006-05-16 WO PCT/US2006/018835 patent/WO2008010784A1/en active Application Filing
-
2007
- 2007-11-13 ZA ZA200709761A patent/ZA200709761B/xx unknown
- 2007-11-15 IL IL187431A patent/IL187431A0/en unknown
- 2007-12-14 NO NO20076456A patent/NO20076456L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2008540691A (ja) | 2008-11-20 |
AU2006344711A1 (en) | 2008-01-24 |
CA2609296A1 (en) | 2006-11-16 |
IL187431A0 (en) | 2011-08-01 |
NO20076456L (no) | 2008-02-13 |
KR20080026109A (ko) | 2008-03-24 |
EP1915139A1 (en) | 2008-04-30 |
US20090269400A1 (en) | 2009-10-29 |
MX2007014363A (es) | 2009-04-15 |
CN101287453A (zh) | 2008-10-15 |
EA200702518A1 (ru) | 2008-04-28 |
WO2008010784A1 (en) | 2008-01-24 |
ZA200709761B (en) | 2008-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0614080A2 (pt) | Composição e método para a preparação de uma cefalosporina nanoparticulada, para o tratamento de doença bacteriana e para a prevenção e/ou tratamento de osteoporose | |
Prasanna et al. | Sustained release of amoxicillin from hydroxyapatite nanocomposite for bone infections | |
Pajares-Chamorro et al. | Silver-doped bioactive glass particles for in vivo bone tissue regeneration and enhanced methicillin-resistant Staphylococcus aureus (MRSA) inhibition | |
Uskoković et al. | In vitro analysis of nanoparticulate hydroxyapatite/chitosan composites as potential drug delivery platforms for the sustained release of antibiotics in the treatment of osteomyelitis | |
Sivakumar et al. | Incorporation of antimicrobial macromolecules in acrylic denture base resins: a research composition and update | |
Ernst et al. | Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions | |
Barreras et al. | Chitosan nanoparticles enhance the antibacterial activity of chlorhexidine in collagen membranes used for periapical guided tissue regeneration | |
Saifullah et al. | Controlled-release approaches towards the chemotherapy of tuberculosis | |
Petersen | Triclosan antimicrobial polymers | |
WO2007086914A3 (en) | Nanoparticulate clopidogrel formulations | |
NO20080202L (no) | Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer | |
Palanikumar et al. | Influence of particle size of nano zinc oxide on the controlled delivery of Amoxicillin | |
BRPI0416239A (pt) | método para preparar partìculas de submìcron de paclitaxel | |
BRPI0807569A8 (pt) | Péletes compreendendo uma matriz de substância ativa resistentes ao suco gástrico | |
Sun et al. | Preparation and application of collagen scaffold-encapsulated silver nanoparticles and bone morphogenetic protein 2 for enhancing the repair of infected bone | |
MXPA05014158A (es) | Estructuras absorbentes que comprenden particulas polimericas superabsorbentes recubiertas. | |
PE20080899A1 (es) | Composiciones en nanoparticulas | |
Tiwari et al. | Review on surface treatment for implant infection via gentamicin and antibiotic releasing coatings | |
Yun et al. | Application of antibacterial nanoparticles in orthodontic materials | |
Chai et al. | Poly‐cyclodextrin functionalized porous bioceramics for local chemotherapy and anticancer bone reconstruction | |
Spoiala et al. | The SiO2/ZnO composite materials for cosmetic creams | |
Abdulkareem | Role of Potential Nanomateriales in Reducing Bacterial Resistance against Antibiotics (A Review). | |
EA200800092A1 (ru) | Композиции в виде наночастиц и с контролируемым высвобождением, включающие арил-гетероциклические соединения | |
Lewis | Antibiotic-free antimicrobial poly (methyl methacrylate) bone cements: A state-of-the-art review | |
Yu et al. | Comprehensive biosafety assessment of Ag-ZnO/talc nanomaterials: Implications for antibacterial applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA. |
|
B11Z | Dismissal: petition dismissal - article 216, par 2 of industrial property law |
Free format text: REFERENTE A PETICAO NO 20070163006/RJ DE 19/11/2007. |
|
B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: O DESPACHO 6.7 DA RPI 2140 DE 10/01/2012 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0. |
|
B11M | Decision cancelled [chapter 11.13 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |